SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-033598
Filing Date
2024-04-17
Accepted
2024-04-17 08:30:10
Documents
17
Period of Report
2024-04-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0203971-8k_abvcbio.htm   iXBRL 8-K 28198
2 DEFINITIVE LICENSE AGREEMENT BETWEEN THE COMPANY AND ONCOX BIOPHARMA, INC ea020397101ex10-1_abvcbio.htm EX-10.1 37504
3 DEFINITIVE LICENSE AGREEMENT BETWEEN RGENE AND ONCOX BIOPHARMA, INC. ea020397101ex10-2_abvcbio.htm EX-10.2 37981
4 PRESS RELEASE ea0203971ex99-1_abvcbio.htm EX-99.1 20476
5 GRAPHIC ex99-1_001.jpg GRAPHIC 2336
  Complete submission text file 0001213900-24-033598.txt   322380

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE abvc-20240417.xsd EX-101.SCH 3021
7 XBRL LABEL FILE abvc-20240417_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE abvc-20240417_pre.xml EX-101.PRE 22363
20 EXTRACTED XBRL INSTANCE DOCUMENT ea0203971-8k_abvcbio_htm.xml XML 3568
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

IRS No.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 24849418
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)